Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
Achievement of glycemic control is the major therapeutic aim to prevent or delay the onset and progression of diabetes related complications. Insulin therapy represents a cornerstone in the treatment of diabetes and has been used widely for achieving glycemic goals. The aim for insulin therapy is to...
Guardado en:
Autores principales: | Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e2877a380c0d452b888d1d55d75e3431 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
por: M. V. Shestakova, et al.
Publicado: (2021) -
Insulin degludec is a new ultra-long-acting insulin analogue
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014) -
Modern basal insulins: an ongoing story or the start of a new era?
por: Ivan Ivanovich Dedov
Publicado: (2015) -
Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2015) -
Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
por: Lyudmila Alexandrovna Suplotova, et al.
Publicado: (2015)